BACKGROUND: Aviptadil, a synthetic form of human vasoactive intestinal peptide, has entered clinical trials to treat critical coronavirus disease 2019 pneumonia with respiratory failure. Vasoactive intestinal peptide protects the lung against a broad array of injuries by binding to the vasoactive intestinal peptide receptor 1 receptor of alveolar type II cells, the cells that severe acute respiratory syndrome coronavirus 2 binds to. As the role of Aviptadil in treating pregnant patients with critical coronavirus disease 2019 pneumonia is unknown, the authors report successful treatment in such a patient who is ineligible for phase 3 trials of Aviptadil.

CASE SUMMARY: Under an open-label Food and Drug Administration-approved Expanded Access Protocol NCT04453839, a 32-year-old female patient Gravida 6 Para 4 at 27-week gestation, body mass index 42.5 kg/m², admitted to the ICU of a quaternary care hospital with critical coronavirus disease 2019 was treated in January 2021 and followed for 4 months post-ICU admission. Standard of care included remdesivir, methylprednisolone, enoxaparin, and inhaled epoprostenol. In addition, the patient received three successive 12-hour IV infusions of Aviptadil at 50/100/150 pmol/kg/hr escalating doses, per randomized clinical trial NCT04311697. Human subjects’ protection was overseen by the Institutional Review Board of the Houston Methodist Hospital. The patient was enrolled in the treatment and was given informed consent approved by the Food and Drug Administration and the Institutional Review Board. Data on the patient was incorporated based on her consent for de-identified data to be used in research given at the time of hospital admission in a manner approved by the Institutional Review Board (PRO00025607). Baseline inflammatory markers, arterial blood gases, radiologic imaging, oxygen requirements, PaO₂/FiO₂, continuous fetal monitoring at baseline, throughout the patient’s treatment with the investigational drug, and throughout the patient’s hospital course.

CONCLUSION: The rapid clinical improvement seen in this patient treated with IV vasoactive intestinal peptide is consistent with the theory that vasoactive intestinal peptide protects the alveolar type II cell, ameliorates cytokine storm, and improves oxygenation in acute lung injury. This specific role of vasoactive intestinal peptide in the lung may be vital to combating the lethal effects of severe acute respiratory syndrome coronavirus 2 infection. In addition, the role of vasoactive intestinal peptide in the human maternal-fetal interface suggests that vasoactive intestinal peptide is a safe treatment of severe coronavirus disease 2019 respiratory failure during pregnancy.

KEY WORDS: acute respiratory distress syndrome; alveolar type II; coronavirus disease 2019; severe acute respiratory syndrome coronavirus 2; surfactant; vasoactive intestinal peptide

Jihad Georges Youssef, MD
Mohammad Z. Bitar, MD
Faisal Zahiruddin, DO
Mukhtar Al-Saadi, MD, EdD
Mahmoud Elshawwaf, MD
Simon Yau, MD
Ahmad Goodarzi, MD
Jonathan C. Javitt, MD, MPH
A viptadil, a synthetic form of human vasoactive intestinal peptide (VIP), has been awarded Food and Drug Administration Fast Track Designation for the treatment of severe coronavirus disease 2019 (COVID-19) respiratory failure and has entered clinical trials in the United States and internationally. VIP has previously demonstrated effectiveness in the treatment of acute respiratory distress syndrome.

![Radiographic appearance and blood oxygen saturation before and after treatment. BiPAP = bilevel positive airway pressure, BNP = brain natriuretic peptide, CRP = c-reactive protein, HFNC = high-flow nasal cannula, IL-6 = interleukin, LDH = lactate dehydrogenase, P/F ratio = ratio of P_{O_2}/F_{O_2}.)](image)

| Day of Admission | Day of ICU Transfer/Aviptadil | Day 1 | Day 2 |
|------------------|------------------------------|-------|-------|
| Portable Chest X-Ray | ![Image](image) | ![Image](image) | ![Image](image) |

| LDH U/L | 275 | 334 | 365 | 433 |
| CRP mg/dL | 11.18 | 18.95 | 12.85 | 7.93 |
| Troponin | <0.0006 | | | |
| BNP | <3 | | | |
| IL-6 pg/mL | 65 | 17.2 | 47.8 | 5.7 |
| D-dimer ug/mL | 1.76 | 0.62 | 1.69 | 3.38 |
| Ventilation | Nasal Canula 3L/min | BiPAP 12/6 | HFNC 45L/70% | HFNC 40/65% |
| P/F Ratio | 223 | 123 | 151 | | |

| Portable Chest X-Ray | ![Image](image) | ![Image](image) | ![Image](image) |

| LDH U/L | 384 | 385 | 342 | 284 |
| CRP mg/dL | 8.67 | 4.33 | 1.64 | <0.3 |
| Troponin | | | | |
| BNP | | | | |
| IL-6 pg/mL | 5.9 | <2.5 | <2.5 | <2.5 |
| D-dimer ug/mL | 6.62 | 5.72 | 3.6 | 3.3 |
| Ventilation | HFNC 40L/40% | HFNC 15L/45% | Nasal Canula 2L/min | Room Air |
| P/F Ratio | 228 | 208 | 348 | |

Figure 1. Radiographic appearance and blood oxygen saturation before and after treatment. BiPAP = bilevel positive airway pressure, BNP = brain natriuretic peptide, CRP = c-reactive protein, HFNC = high-flow nasal cannula, IL-6 = interleukin, LDH = lactate dehydrogenase, P/F ratio = ratio of P_{O_2}/F_{O_2}. 

www.ccejournal.org
(ARDS) related to sepsis, sarcoid, and pulmonary hypertension (1–4).

**CLINICAL REPORT**

A 32-year-old female patient, Gravida 6 Para 4 at 27-week gestation, body mass index 42.5 kg/m², presented to the emergency department with 4 days of loss of appetite, nausea, vomiting along with shortness of breath, cough, high-grade fever, and hypoxemia of 88%. The patient contracted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), confirmed by positive reverse transcriptase-quantitative polymerase chain reaction from a nasopharyngeal swab, with refractory acute hypoxemic respiratory failure. Chest CT showed multilobar patchy consolidation and ground-glass opacities with no pulmonary embolism. The patient was admitted to the high-risk obstetrics ward, where she received remdesivir, methylprednisolone, and enoxaparin. The patient was not a candidate for monoclonal antibodies or convalescent plasma. Therefore, no other experimental therapies were administered.

Despite therapy 3 days later, the patient developed worsening hypoxemic respiratory failure and was transferred to the ICU on high-flow nasal cannula (oxygen 60 L/min with 
\( \text{Fi}O_2 \) 100%) alternating with bilevel positive airway pressure (BiPAP) in anticipation of needing intubation to avoid patient self-inflicted lung injury seen in COVID-19. Inflammatory markers (reflecting cytokine storm) were elevated on the day of admission and day of ICU transfer, despite systemic steroids and remdesivir. The echocardiogram was normal.

The patient received three successive 12-hour IV infusions of Aviptadil at 50/100/150 pmol/kg/hr. This treatment was associated with dramatically improved oxygenation, inflammatory markers, and radiologic pneumonitis (Fig. 1). These improvements allowed for the weaning of BiPAP to nasal cannula after administration of the second dose of Aviptadil. Continuous fetal monitoring throughout her hospital stay showed no adverse outcomes (Fig. 2). The patient was discharged from the ICU 24 hours following the third infusion. Neither the patient nor the clinical staff reported any treatment-associated adverse effects; the patient was discharged home on room air 6 days following the first infusion. Phone call visit revealed patient continued to do quite well on room air and gave full-term birth through vaginal delivery to a healthy 8 lb., 1 ounce, and 18 inches newborn. At 4, 6, and 9 months follow-up visits, both patient and baby continued to be in excellent medical condition (Fig. 3).

**DISCUSSION**

To our knowledge, this is the first reported case of VIP being used to treat a critical COVID-19 respiratory failure in a morbidly obese pregnant patient who is at increased risk of severe pregnancy complications, including preterm birth, low birth weight, and higher mortality (5), with rapid clinical and radiographic

---

*Figure 2. Fetal monitoring. bpm = beats per minute, FHR = fetal heart rate, UA = uterine activity.*
**Figure 3.** Follow-up at 1, 3, and 4 mo. ARDS = acute respiratory distress syndrome, COVID-19 = coronavirus disease 2019, DL/VA = ratio of DLCO to alveolar volume, DLCO_SB= diffusing capacity for carbon monoxide single breath, DLCOcSB = diffusing capacity for carbon monoxide corrected for hemoglobin single breath, FEF25-75% = forced expiratory flow, Fev1 = forced expiratory volume in 1 s, FRCpl = functional residual capacity by plethysmography, FVC = force vital capacity, Hb = hemoglobin, IC = inspiratory capacity, KCOc_SB = carbon monoxide transfer coefficient corrected for hemoglobin single breath, LLN = lower limit of normal, PEF = peak expiratory flow, PFTS = pulmonary function test(s), Raw = airway resistance, R0.5IN = raw at a flow rate of 0.5 L/s, RV = residual volume, sGaW = specific airway conductance, sR0.5IN = specific R0.5IN, TLC = total lung capacity, VA_SB = alveolar volume single breath, VC = vital capacity.

| PFTS 4 months after COVID-19ARDS | Ref | LLN | Pre |
|----------------------------------|-----|-----|-----|
| **Level date**                  |     |     | 05/24/21 |
| **Level time**                  |     |     | 10:37AM |
| **FEV1**                        | L   | 2.42| 1.87 | 2.51 |
| **FVC**                         | L   | 2.85| 2.20 | 2.67 |
| **FEV1/FVC**                    | %   | 85  | 74  | 94  |
| **FEF25-75%**                   | L/s | 2.89| 1.64| 4.22 |
| **PEF**                         | L/s | 6.32| 4.50| 6.32 |
| **VC**                          | L   | 2.85| 2.20| 2.03 |
| **ERV**                         | L   | 1.17| 1.17| 0.20 |
| **FRCpl**                       | L   | 2.50| 1.68| 1.58 |
| **IC**                          | L   | 1.98| 1.98| 1.83 |
| **RV**                          | L   | 1.33| 0.76| 1.38 |
| **RV%TLC**                      | %   | 30  | 21  | 41  |
| **TLC**                         | L   | 4.44| 3.45| 3.41 |
| **Raw**                         | cmH2O*s/L | 3.06| 3.06| 4.14 |
| **R0.5IN**                      | cmH2O*s/L | 3.06| 3.06| 2.52 |
| **sR0.5IN**                     | cmH2O*s | 1  | 1  | 4.55 |
| **sGaw**                        | 1/(cmH2O*s) | 0.10| 0.10| 0.13 |
| **DLCO_SB**                     | ml/(min*mmHg) | 23.39| 16.89| 17.86 |
| **DLCOcSB**                     | ml/(min*mmHg) | 23.39| 16.89| 17.86 |
| **DL/VA**                       | ml/(min*mmHg*L) | 5.01| 3.69| 4.78 |
| **KCOc_SB**                     | ml/(min*mmHg*L) | 5.01| 3.69| 4.78 |
| **VA_SB**                       | L   | 4.57| 3.47| 3.74 |
| **Hb**                          | g(Hb)/dl | 13.40 | | |
improvement. In a 21-patient report of those affected with COVID-19 respiratory failure and those with checkpoint inhibitor pneumonitis, patients who were given VIP were treated successfully and saw a dramatic improvement in their outcomes (6, 7).

Early COVID-19 lung injury is characterized by a remarkable degree of hypoxemia in the absence of overwhelming pneumonia, suggesting primary pulmonary gas exchange mechanism damage. The SARS-CoV-2 virus specifically attacks alveolar type II (ATII) cells by binding to angiotensin converting enzyme 2 receptors (8–12). Since its discovery in 1970 by Said and Mutt (13), VIP is shown to prevent ATII cells apoptosis in models of lung injury (14). Unlike synthetic anti-cytokines, such as anti-interleukin-6 drugs, VIP has been demonstrated to play a specific role in preserving surfactant production in the lung and in protecting type 2 alveolar cells (14–19). Accordingly, VIP and longer-acting VIP modifications have been proposed as respiratory therapeutics (20). Loss of ATII cells reduces the lung’s oxygenation capacity, mainly because the ATII cell is responsible for the production and recycling of surfactants and its other roles in supporting the pulmonary epithelium (15). Furthermore, VIP is a pleiotropic neuropeptide synthesized and released at the maternal-fetal interface. Animal models revealed that the treatment of pregnant mice with VIP at the first week of gestation resulted in more viable implantations. In pregnant humans, cytotrophoblast and syncytiotrophoblast cells of first- and third-trimester placenta and trophoblast cell lines also express VIP (21). Deficiencies in VIP production have been associated with recurrent pregnancy loss (22). The preservation of ATII cells increased pulmonary surfactant and anti-cytokine properties likely played a significant role in the dramatic recovery of this 27 weeks pregnant patient with COVID-19 ARDS, leading to full-term pregnancy and delivery of a healthy newborn. A recently published randomized clinical trial suggests that treatment with Aviptadil improves the likelihood of recovery from respiratory failure and survival at 60 days post-treatment in critically ill patients with respiratory failure caused by COVID-19 (23).

CONCLUSIONS

The rapid clinical improvement seen in this patient treated with Aviptadil is consistent with the theory that VIP protects the ATII cell, ameliorates cytokine storm, and improves oxygenation in acute lung injury. This highly specific role of VIP in the lung may be vital in combating the lethal effects of SARS-CoV-2 infection. In addition, the role of VIP in the human maternal-fetal interface suggests that VIP is a safe treatment of severe COVID-19 respiratory failure during pregnancy.

REFERENCES

1. Jihad GY, Sami S, George Y, et al: Treatment of acute respiratory distress syndrome with vasoactive intestinal peptide. J Infect Dis Treat 2021; ?
2. Prasse A, Zissel G, Lützen N, et al: Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med 2010; 182:540–548
3. Petkova V, Mosgoeller W, Ziesche R, et al: Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003; 111:1339–1346
4. Leuchte HH, Baezner C, Baumgartner RA, et al: Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 2008; 32:1289–1294
5. José V, Shabina A, Robert BG, et al: Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: The INTERCOVID multinational cohort study. JAMA Pediatr 2021; 175:817–826
6. Youssef JG, Javitt JC, Lavin P, et al: VIP in the treatment of critical Covid-19 with respiratory failure in patients with severe...
comorbidity: A prospective externally-controlled trial. *J Infect Dis Treat* 2021; 7
7. Frye BC, Meiss F, von Bubnoff D, et al: Vasoactive intestinal peptide in checkpoint inhibitor-induced pneumonitis. *N Engl J Med* 2020; 382:2573–2574
8. Said SI: Vasoactive intestinal peptide in the lung. *Ann N Y Acad Sci* 1988; 527:450–464
9. Said SI: VIP as a modulator of lung inflammation and airway constriction. *Am Rev Respir Dis* 1991; 143:S22–S24
10. Said SI, Dickman KG: Pathways of inflammation and cell death in the lung: Modulation by vasoactive intestinal peptide. *Regul Pept* 2000; 93:21–29
11. Javitt J, Youssef JG: VIP: A COVID-19 Therapeutic That Blocks Coronavirus Replication. Available at: https://ssrn.com/abstract=3670129. Accessed August 9, 2020
12. Mossel EC, Wang J, Jeffers S, et al: SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells. *Virology* 2008; 372:127–135
13. Said SI, Mutt V: Potent peripheral and splanchnic vasodilator peptide from normal gut. *Nature* 1970; 225:863–864
14. Onoue S, Ohmori Y, Endo K, et al: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide attenuate the cigarette smoke extract-induced apoptotic death of rat alveolar L2 cells. *Eur J Biochem* 2004; 271:1757–1767
15. Mason RJ: Pathogenesis of COVID-19 from a cell biology perspective. *Eur Respir J* 2020; 55:2000607
16. Li L, Luo ZQ, Zhou FW, et al: Effect of vasoactive intestinal peptide on pulmonary surfactants phospholipid synthesis in lung explants. *Acta Pharmacol Sin* 2004; 25:1652–1658
17. Li L, She H, Yue SJ, et al: Role of c-fos gene in vasoactive intestinal peptide promoted synthesis of pulmonary surfactant phospholipids. *Regul Pept* 2007; 140:117–124
18. Li L, Hua S, Yue S, et al: Vasoactive intestinal polypeptide induces surfactant protein A expression in ATII cells through activation of PKC/c-Fos pathway. *Peptides* 2010; 31:2016–2051
19. Temerozo JR, Sacramenta Q, Fintelman-Rodrigues N, et al: The neuropeptides VIP and PACAP inhibit SARS-CoV-2 replication in monocytes and lung epithelial cells, decrease the production of proinflammatory cytokines, and VIP levels are associated with survival in severe Covid-19 patients *bioRxiv*. Available at: https://www.biorxiv.org/content/10.1101/2020.07.25.220806v6.
20. Mathioudakis A, Chatzimavridou-Grigoriadou V, Evangelopoulou E, et al: Vasoactive intestinal peptide inhaled agonists: Potential role in respiratory therapeutics. *Hippokratia* 2013; 17:12–16
21. Ramhorst R, Calo G, Paparini D, et al: Control of the inflammatory response during pregnancy: Potential role of VIP as a regulatory peptide. *Ann N Y Acad Sci* 2019; 1437:15–21
22. Fraccaroli L, Grasso E, Hauk V, et al: Defects in the vasoactive intestinal peptide (VIP)/VPAC system during early stages of the placental-maternal leucocyte interaction impair the maternal tolerogenic response. *Clin Exp Immunol* 2012; 170:310–320
23. Youssef JG, Lee R, Javitt J, et al: Intravenous Aviptadil Is Associated With Increased Recovery and Survival in Patients With COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial. 2021. Available at: https://ssrn.com/abstract=3830051. Accessed August 7, 2021